Cassava Sciences, Inc.
NASDAQ:SAVA
Overview | Financials
Company Name | Cassava Sciences, Inc. |
Symbol | SAVA |
Currency | USD |
Price | 25.34 |
Market Cap | 1,215,716,908 |
Dividend Yield | 0% |
52-week-range | 8.79 - 42.2 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Remi Barbier |
Website | https://www.cassavasciences.com |
An error occurred while fetching data.
About Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD